Trial Profile
Primary Prevention of Stroke in Children With Sickle Cell Disease in Sub-Saharan Africa II
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2021
Price :
$35
*
At a glance
- Drugs Hydroxycarbamide (Primary)
- Indications Stroke; Transient ischaemic attacks
- Focus Therapeutic Use
- Acronyms SPRING
- 01 Feb 2021 Trial design published in the Pediatric Hematology and Oncology.
- 28 Apr 2020 Status changed from active, no longer recruiting to completed.
- 27 Aug 2018 Status changed from recruiting to active, no longer recruiting.